Abstract:Over the last two decades, cancer researchers have taken the promise offered by the Human Genome Project and have expanded its capacity to use sequencing to identify the genomic alterations that give rise to and sustain individual tumors. This expansion has allowed researchers to identify and target highly recurrent alterations in specific cancer contexts, such as EGFR mutations in non-small cell lung cancer (Lynch et al, N Engl J Med 350:2129-2139, 2004; Sharifnia et al., Proc Natl Acad Sci U S A 111:18661-18666, 2014), BCR-ABL translocations in chronic myeloid leukemia (Deininger, Pharmacol Rev 55:401-423. https://doi.org/10.1124/pr.55.3.4 , 2003; Druker et al, N Engl J Med 344. 1038-1042, 2001; Druker et al, N Engl J Med 344:1031-1037. https://doi.org/10.1056/NEJM200104053441401 , 2001), or HER2 amplifications in breast cancer (Slamon et al, N Engl J Med 344:783-792. https://doi.org/10.1056/NEJM200103153441101 , 2001; Solca et al, Beyond trastuzumab: second-generation targeted therapies for HER-2-positive breast cancer. In: Sibilia M, Zielinski CC, Bartsch R, Grunt TW (eds) Drugs for HER-2-positive breast cancer. Springer, Basel, pp 91-107, 2011). Despite these advances in our capacity to identify the genetic alterations that drive tumor initiation, survival, and proliferation, our ability to target these alterations to provide effective treatment options for patients in need, particularly those with rare or advanced cancers, remains limited (Gould et al, Nat Med 21:431-439. https://doi.org/10.1038/nm.3853 , 2015). Patient-derived models of cancer offer one potential mechanism to overcome this barrier between the bench and bedside. Through the development and testing of patient-derived models of cancer, functional genomics efforts can identify tumor-specific drug sensitivities and thereby provide a connection between tumor genetics and effective therapeutics for patients in need of treatment options.Recognizing that cancer is a multifaceted set of disease states, the development of personalized models of cancer that can be used to compare treatment options, identify tumor-specific vulnerabilities, and guide clinical decision-making has tremendous potential for improving patient outcomes. This chapter will describe a representative set of patient-derived models of cancer, reviewing each of their strengths and weaknesses and highlighting how selecting a model to suit a specific question or context is critical. Each model comes with a unique set of pros and cons, making them more or less appropriate for each specific research or clinical question. As each model can be leveraged to gain new insights into cancer biology, the key to their deployment is to identify the most appropriate model for a specific context, while carefully considering the strengths and limitations of the selected model. When used appropriately, patient-derived models may prove to be the missing link needed to bring the promise of personalized oncology to fruition in the clinic.

Patient-derived melanoma models

A Melanoma Patient-Derived Xenograft Model

Pre-clinical modeling of cutaneous melanoma

Melanoma models for the next generation of therapies

Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

A preclinical model of cutaneous melanoma based on reconstructed human epidermis

Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Establishing Human Skin Grafts in Mice As Model for Melanoma Progression.

A Reconstructed Human Melanoma-in-Skin Model to Study Immune Modulatory and Angiogenic Mechanisms Facilitating Initial Melanoma Growth and Invasion

Patient-Derived In Vitro and In Vivo Models of Cancer

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

The Essential Factors of Establishing Patient-derived Tumor Model.

Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis

Phenotypic diversity of patient-derived melanoma populations in stem cell medium

Patient-derived model systems and the development of next-generation anticancer therapeutics

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells

Abstract PR02: Humanized Mouse Melanoma Model Using Patient-Derived Xenografts

Patient‐Derived Melanoma Immune‐Tumoroids as a Platform for Precise High throughput Drug Screening

Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics